ArticleJournal of substance use and addiction treatment2025
Different forms of stigma and rural primary care professionals' willingness to prescribe buprenorphine.
Article in Journal of substance use and addiction treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Does perceived stigma impact opioid use disorder treatment uptake? A cross-sectional secondary analysis of buprenorphine engagement among syringe service program participants.Addiction science & clinical practice · 2026Trial
- Brief Prescribing Support and Buprenorphine Adoption in Rural Primary Care: A Cluster Randomized Clinical Trial.JAMA network open · 2026Trial
- Health Care Professional Willingness to Treat Opioid Use Disorder vs Type 2 Diabetes in Primary Care.JAMA network open · 2025Trial
- Implementation Outcomes of Low Threshold Care for Persons with Opioid Use Disorders.Journal of general internal medicine · 2026Article
- Reducing Buprenorphine Misinformation as a Strategy to Improve Adoption in Primary Care.Substance use & misuse · 2026Article
- A scoping review of implementation strategies to reduce stigma toward people who use substances in healthcare settings.Journal of substance use and addiction treatment · 2026Article
- Peer Prescriber Support Strategies to Increase Buprenorphine Prescribing in Primary Care.Substance use & addiction journal · 2026Article
- Rural Clinicians Efforts to Maintain Relationship-Centered Care Amidst Conflicting Tensions with Inherited Opioid Prescribing Practices.Journal of general internal medicine · 2026Article
- Private Equity Acquisition and Buprenorphine Prescribing.JAMA network open · 2026Article
- Medication Approaches for Patients With Opioid Use Disorders: Differences Between Primary Care Clinics and Specialty Addiction Treatment Programs.Journal of addiction medicineArticle
- Pain Management Strategies for Patients Receiving Extended-Release Buprenorphine for Opioid Use Disorder: A Scoping Review.Substance use : research and treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionBuprenorphine and other medications for opioid use disorder (MOUD) are highly effective but substantially under prescribed in the rural United States. Among the most cited barriers to buprenorphine prescribing is stigma, yet little progress has been made in developing successful strategies to reduce stigma and increase access to life-saving medication. One of the key challenges to developing successful implementation strategies is understanding the different types of stigma that limit implementation.
methodsThis study draws from qualitative interviews with 23 primary care professionals (PCPs) in rural Ohio. We conducted semi-structured interviews focused on prior experiences with buprenorphine, willingness to prescribe it, prior buprenorphine training, and barriers to prescribing. Thematic analysis resulted in 3 forms of stigma that must be addressed to improve implementation.
resultsPCPs discussed 3 key forms of stigma that limit buprenorphine prescribing in rural areas: 1) stigma towards patients-PCPs feared being harmed by patients with opioid use disorder (OUD) if they began prescribing buprenorphine; 2) stigma towards providers-PCPs believed their clinics would be stigmatized if they began treating addiction; and 3) stigma towards buprenorphine-PCPs worried they might unintentionally harm patients through prescribing a partial opioid agonist.
conclusionsStigma remains a critical barrier to buprenorphine prescribing among rural PCPs but is not limited to negative attitudes towards people with OUD. Buprenorphine is also stigmatized and PCPs fear becoming stigmatized if they prescribe the medication. Implementation research is urgently needed to test whether multicomponent stigma-reduction strategies increase access to buprenorphine in rural communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.